Liane O Dallalzadeh, George A Villatoro, Lillian Chen, Myung S Sim, Mansoor Movaghar, Shira L Robbins, Justin N Karlin, Monica R Khitri, Federico G Velez, Bobby S Korn, Joseph L Demer, Daniel B Rootman, David B Granet, Don O Kikkawa
PURPOSE: To assess and quantify teprotumumab's effect on thyroid eye disease-related strabismus by change in measured horizontal and vertical deviations and change in extraocular motility. METHODS: We reviewed a series of patients with thyroid eye disease-related strabismus treated with teprotumumab. Exclusion criteria included age under 18 years, strabismus of alternate etiology, or thyroid eye disease-related reconstructive surgery during the treatment course...
February 2, 2024: Ophthalmic Plastic and Reconstructive Surgery